Stanozolol

Overview

Stanozolol (abbrev. Stz), sold under many brand names, is a synthetic androgen and anabolic steroid (AAS) medication derived from dihydrotestosterone (DHT). It is used to treat hereditary angioedema. It was developed by American pharmaceutical company Sterling-Winthrop in 1962, and has been approved by the U.S. Food and Drug Administration for human use, though it is no longer marketed in the United States. It is also used in veterinary medicine. Stanozolol has mostly been discontinued, and remains available in only a few countries. It is given by mouth in humans or by injection into muscle in animals.[1–4] WP

Unlike most AAS, stanozolol is not esterified and is sold as an aqueous suspension, or in oral tablet form. The drug has a high oral bioavailability, due to a C17α alkylation which allows the hormone to survive first-pass liver metabolism when ingested. It is because of this that stanozolol is also sold in tablet form.[3][5] WP

Stanozolol is one of the AAS commonly used as performance-enhancing drugs and is banned from use in sports competition under the auspices of the World Anti-Doping Agency (WADA). It is an anabolic steroid that is known to have a diuretic effect. Additionally, stanozolol has been highly restricted in US horse racing.[6][7][8] WP

Uses, dosage and effects

Medical uses

Stanozolol has been used with some success to treat venous insufficiency. It stimulates blood fibrinolysis and has been evaluated for the treatment of the more advanced skin changes in venous disease such as lipodermatosclerosis. Several randomized trials noted improvement in the area of lipodermatosclerosis, reduced skin thickness, and possibly faster ulcer healing rates with stanozolol. It is also being studied to treat hereditary angioedema, osteoporosis, and skeletal muscle injury.[9–12] WP

Non-medical uses

Stanozolol is used for physique- and performance-enhancing purposes by competitive athletes, bodybuilders, and powerlifters.[3] WP

Risks and side effects

Side effects

Side effects of stanozolol include virilization (masculinization), hepatotoxicity, cardiovascular disease, and hypertension.[3] WP

Pharmacology

Pharmacodynamics

As an AAS, stanozolol is an agonist of the androgen receptor (AR), similarly to androgens like testosterone and DHT. Its affinity for the androgen receptor is about 22% of that of dihydrotestosterone. Stanozolol is not a substrate for 5α-reductase as it is already 5α-reduced, and so is not potentiated in so-called "androgenic" tissues like the skin, hair follicles, and prostate gland. This results in a greater ratio of anabolic to androgenic activity compared to testosterone. In addition, due to its 5α-reduced nature, stanozolol is non-aromatizable, and hence has no propensity for producing estrogenic effects such as gynecomastia or fluid retention. Stanozolol also does not possess any progestogenic activity of significance. Because of the presence of its 17α-methyl group, the metabolism of stanozolol is sterically hindered, resulting in it being orally active, although also hepatotoxic.[3][13][14] WP

Multi-receptor activity and stem-cell differentiation WP

In addition to classical AR signaling, in-vitro work with mesenchymal stem-cell micromass cultures shows that stanozolol: WP

• Binds to the progesterone receptor (PR) and to an unidentified membrane receptor that drives Prostaglandin E2 (PGE₂) synthesis via COX-2 induction.[15] WP
• Induces a feed-forward loop in which PGE₂ amplifies BMP2 expression, accelerating osteogenic and chondrogenic differentiation.[15] WP
• Causes sustained phosphorylation of PKCε, an isoform linked to suppression of the hypertrophic cartilage marker MATN1 and to formation of articular-cartilage (interzone) phenotypes.[15] WP

Pharmacological blockade of either PR (mifepristone) or COX-2 (indomethacin) abolishes these effects, confirming that stanozolol’s osteochondral activity requires simultaneous PR signaling and PGE₂-driven crosstalk with the BMP2 pathway.[15] WP

Additionally, stanozolol has been shown to exert activity via estrogen receptor alpha (ERα) in vivo. In a rat model of GnRH agonist-induced growth plate suppression, stanozolol restored chondrocyte proliferation via ERα activation, indicating selective estrogen receptor-mediated effects in growth plate cartilage.[16] WP

Pharmacokinetics

Stanozolol has high oral bioavailability, due to the presence of its C17α alkyl group and the resistance to gastrointestinal and liver metabolism that it results in. The medication has very low affinity for human serum sex hormone-binding globulin (SHBG), about 5% of that of testosterone and 1% of that of DHT. Stanozolol is metabolized in the liver, ultimately becoming glucuronide and sulfate conjugates. Its biological half-life is reported to be 9 hours when taken by mouth and 24 hours when given by intramuscular injection in the form of an aqueous suspension. It is said to have a duration of action of one week or more via intramuscular injection.[17–23] WP

Detection in body fluids

Stanozolol is subject to extensive hepatic biotransformation by a variety of enzymatic pathways. The primary metabolites are unique to stanozolol and are detectable in the urine for up to 10 days after a single 5–10 mg oral dose. Methods for detection in urine specimens usually involve gas chromatography-mass spectrometry or liquid chromatography-mass spectrometry.[24][25][26] WP

Research

Research

Stanozolol has been investigated in the treatment of a number of dermatological conditions including urticaria, hereditary angioedema, Raynaud's phenomenon, cryofibrinogenemia, and lipodermatosclerosis.[27] WP

History

History

In 1962, Stanozolol was brought to market in the US by Winthrop under the tradename "Winstrol" and in Europe by Winthrop's partner, Bayer, under the name "Stromba".[28] WP

Also in 1962, the Kefauver Harris Amendment was passed, amending the Federal Food, Drug, and Cosmetic Act to require drug manufacturers to provide proof of the effectiveness of their drugs before approval. The FDA implemented its Drug Efficacy Study Implementation (DESI) program to study and regulate drugs, including stanozolol, that had been introduced prior to the amendment. The DESI program was intended to classify all pre-1962 drugs that were already on the market as effective, ineffective, or needing further study. The FDA enlisted the National Research Council of the National Academy of Sciences to evaluate publications on relevant drugs under the DESI program.[29][30][31] WP

In June 1970 the FDA announced its conclusions on the effectiveness of certain AAS, including stanozolol, based on the NAS/NRC reports made under DESI. The drugs were classified as probably effective as adjunctive therapy in the treatment of senile and postmenopausal osteoporosis but only as an adjunct, and in pituitary dwarfism (with a specific caveat for dwarfism, "until growth hormone is more available"), and as lacking substantial evidence of effectiveness for several other indications. Specifically, the FDA found a lack of efficacy for stanozolol as "an adjunct to promote body tissue-building processes and to reverse tissue-depleting processes in such conditions as malignant diseases and chronic nonmalignant diseases; debility in elderly patients, and other emaciating diseases; gastrointestinal disorders resulting in alterations of normal metabolism; use during pre-operative and postoperative periods in undernourished patients and poor-risk surgical cases due to traumatism; use in infants, children, and adolescents who do not reach an adequate weight; supportive treatment to help restore or maintain a favorable metabolic balance, as in postsurgical, postinfectious, and convalescent patients; of value in pre- operative patients who have lost tissue from a disease process or who have associated symptoms, such as anorexia; retention and utilization of calcium; surgical applications; gastrointestinal disease, malnourished adults, and chronic illness; pediatric nutritional problems; prostatic carcinoma; and endocrine deficiencies." The FDA gave Sterling six months to stop marketing stanozolol for the indications for which there was no evidence for efficacy, and one year to submit further data for the two indications for which it found probable efficacy.[32] WP

In August and September 1970, Sterling submitted more data; the data was not sufficient but the FDA allowed the drug to continue to be marketed, since there was an unmet need for drugs for osteoporosis and pituitary dwarfism, but Sterling was required to submit more data.[33] WP

In 1980 the FDA removed the dwarfism indication from the label for stanozolol since human growth hormone drugs had come on the market, and mandated that the label for stanozolol and other steroids say: "As adjunctive therapy in senile and postmenopausal osteoporosis. AAS are without value as primary therapy but may be of value as adjunctive therapy. Equal or greater consideration should be given to diet, calcium balance, physiotherapy, and good general health promoting measures." and gave Sterling a timeline to submit further data for other indications it wanted for the drug. Sterling submitted data to the FDA intended to support the effectiveness of Winstrol for postmenopausal osteoporosis and aplastic anemia in December, 1980 and August 1983 respectively. The FDA's Endocrinologic and Metabolic Drugs Advisory Committee considered the data submitted for osteoporosis in two meetings held 1981 and the data for aplastic anemia in 1983.[33][34] WP

In April 1984, the FDA announced that the data was not sufficient, and withdrew the marketing authority for stanozolol for senile and postmenopausal osteoporosis and for raising hemoglobin levels in aplastic anemia.[33][35] WP

In 1988, Sterling was acquired by Eastman Kodak for $5.1 billion and in 1994 Kodak sold the drug business of Sterling to Sanofi for $1.675 billion.[36][37] WP

Sanofi had stanozolol manufactured in the US by Searle, which stopped making the drug in October 2002. Even with no drug in production, Sanofi sold the stanozolol business to Ovation Pharmaceuticals in 2003, along with the two other drugs. At that time, the drug had not been discontinued and was considered a treatment for hereditary angioedema. In March 2009, Lundbeck purchased Ovation[38][39][40] WP

In 2010, Lundbeck withdrew stanozolol from the market in the US; as of 2014 no other company is marketing stanozolol as a pharmaceutical drug in the US but it can be obtained via a compounding pharmacy.[41–44] WP

Pfizer had marketed stanozolol as a veterinary drug; in 2013 Pfizer spun off its veterinary business to Zoetis and in 2014 Pfizer transferred the authorizations to market injectable and tablet forms of stanozolol as a veterinary drug to Zoetis.[45][46][47] WP

It is used in veterinary medicine as an adjunct in the management of wasting diseases, to stimulate the formation of red blood cells, arouse appetite, and promote weight gain, but the evidence for these uses is weak. It is used as a performance-enhancing drug in race horses. Its side effects include weight gain, water retention, and difficulty eliminating nitrogen-based waste products and it is toxic to the liver, especially in cats. Because it may promote the growth of tumors, it is contraindicated in dogs with enlarged prostates.[48] WP

Stanozolol and other AAS were commonly used to treat hereditary angioedema attacks, until several drugs were brought to market specifically for treatment of that disease, the first in 2009: Cinryze, Berinert, ecallantide (Kalbitor), icatibant (Firazyr) and Ruconest. Stanozolol is still used long-term to reduce the frequency of severity of attacks.[43][44][49] WP

Legal status

Generic names

Stanozolol is the generic name of stanozolol in English, German, French, and Japanese and its INN (International Nonproprietary Name), USAN (United States Adopted Name), USP (United States Pharmacopeia), BAN (British Approved Name), DCF (Dénomination Commune Française), and JAN (Japanese Accepted Name), while stanozololum is its name in Latin, stanozololo is its name in Italian and its DCIT (Denominazione Comune Italiana), and estanozolol is its name in Spanish. Androstanazole, androstanazol, stanazol, stanazolol, and estanazolol are unofficial synonyms of stanozolol. It is also known by its former developmental code name WIN-14833.[1][2][50] WP

Brand names

Brand names under which stanozolol is or has been marketed include Anaysynth, Menabol, Neurabol Caps., Stanabolic (veterinary), Stanazol (veterinary), Stanol, Stanozolol, Stanztab, Stargate (veterinary), Stromba, Strombaject, Sungate (veterinary), Tevabolin, Winstrol, Winstrol Depot, and Winstrol-V (veterinary).[1][2] WP

Legal status in the united states

In the United States, like other AAS, stanozolol is classified as a controlled substance under federal regulation; they were included as Schedule III controlled substances under the Anabolic Steroids Control Act of 1990 which was passed as part of the Crime Control Act of 1990.[51] WP

Doping in sports

Stanozolol and other synthetic steroids were first banned by the International Olympic Committee and the International Association of Athletics Federations in 1974, after methods to detect them had been developed. There are many known cases of doping in sports with stanozolol by professional athletes. Stanozolol is especially widely used by the athletes from post-Soviet countries. As of 2015, it is banned by World Anti-Doping Agency and United States Anti-Doping Agency.[52][53][54] WP⚠ Wikipedia itself has flagged this text: citation needed.

Chemistry

Formula

C21H32N2O PC

Molar mass (g/mol)

328.5 PC

IUPAC name (computed by PubChem)

(1S,2S,10S,13R,14S,17S,18S)-2,17,18-trimethyl-6,7-diazapentacyclo[11.7.0.02,10.04,8.014,18]icosa-4(8),5-dien-17-ol PC

SMILES

C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C)O)CC[C@@H]4[C@@]3(CC5=C(C4)NN=C5)C PC

InChIKey

LKAJKIOFIWVMDJ-IYRCEVNGSA-N PC

PubChem CID

25249

Harm reduction information

No harm reduction data is on file for this compound yet. That means no dose, timing or combination data from PsychonautWiki or TripSit. Please don't guess a dose from similar compounds. If you have taken it and feel unwell, contact emergency services or a poison control center.

User reports

Pop culture

No references added yet.

Sources

1. Other Index Nominum 2000: International Drug Directory. 2000
2. Other Stanozolol - Drugs.com
3. Other Llewellyn W. Anabolics. 2011
4. Journal / agency Drugs@FDA: FDA Approved Drug Products
5. Other stanozolol (CHEBI:9249)
6. Other Anabolic Steroids Still an Issue in U.S. Horse Racing. 2015-02-13
7. Other Win, Place, and Dope. 1 May 2009
8. Other Anonymous. Model Rules Ver 9.5
9. Journal / agency Burnand K, Clemenson G, Morland M, Jarrett PE, Browse NL. Venous lipodermatosclerosis: treatment by fibrinolytic enhancement and elastic compression. British Medical Journal. January 1980. doi:10.1136/bmj.280.6206.7 · PMID 6986945 · PMC1600523
10. Journal / agency McMullin GM, Watkin GT, Coleridge Smith PD, Scurr JH. Efficacy of fibrinolytic enhancement with stanozolol in the treatment of venous insufficiency. The Australian and New Zealand Journal of Surgery. April 1991. doi:10.1111/j.1445-2197.1991.tb00217.x · PMID 2018441
11. Journal / agency Sloane DE, Lee CW, Sheffer AL. Hereditary angioedema: Safety of long-term stanozolol therapy. The Journal of Allergy and Clinical Immunology. September 2007. doi:10.1016/j.jaci.2007.06.037 · PMID 17765757
12. Journal / agency Tingus SJ, Carlsen RC. Effect of continuous infusion of an anabolic steroid on murine skeletal muscle. Medicine and Science in Sports and Exercise. April 1993. PMID 8479303
13. Journal / agency Kicman AT. Pharmacology of anabolic steroids. British Journal of Pharmacology. June 2008. doi:10.1038/bjp.2008.165 · PMID 18500378 · PMC2439524
14. Other Doods HN. Receptor Data for Biological Experiments: A Guide to Drug Selectivity. 1991
15. Other Mori D. The role of stanozolol in the stimulation of cellular mechanisms for osteochondral regeneration. 2020
16. Journal / agency Zhu S, Li Y, Ma H, Huang T, Luo H, Dou J, Du M. Stanozolol regulates proliferation of growth plate chondrocytes via activation of ERα in GnRHa-treated adolescent rats. J Pediatr Endocr Met. 2011. doi:10.1515/jpem.2011.183 · PMID 21823523
17. Journal / agency Maini AA, Maxwell-Scott H, Marks DJ. Severe alkalosis and hypokalemia with stanozolol misuse. The American Journal of Emergency Medicine. February 2014. doi:10.1016/j.ajem.2013.09.027 · PMID 24521609
18. Other Bilezikian JP, Raisz LG, Rodan GA. Principles of Bone Biology, Two-Volume Set. 19 January 2002
19. Other Herron A, Brennan TK. The ASAM Essentials of Addiction Medicine. 18 March 2015
20. Journal / agency Saartok T, Dahlberg E, Gustafsson JA. Relative binding affinity of anabolic-androgenic steroids: comparison of the binding to the androgen receptors in skeletal muscle and in prostate, as well as to sex hormone-binding globulin. Endocrinology. June 1984. doi:10.1210/endo-114-6-2100 · PMID 6539197
21. Other Hsu WH. Handbook of Veterinary Pharmacology. 25 April 2013
22. Other Ruiz P, Strain EC. Lowinson and Ruiz's Substance Abuse: A Comprehensive Textbook. 2011
23. Other Thieme D, Hemmersbach P. Doping in Sports. 18 December 2009
24. Journal / agency Mateus-Avois L, Mangin P, Saugy M. Use of ion trap gas chromatography-multiple mass spectrometry for the detection and confirmation of 3'hydroxystanozolol at trace levels in urine for doping control. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. February 2005. doi:10.1016/j.jchromb.2004.11.033 · PMID 15664350
25. Journal / agency Pozo OJ, Van Eenoo P, Deventer K, Lootens L, Grimalt S, Sancho JV, Hernández F, Meuleman P, Leroux-Roels G, Delbeke FT. Detection and structural investigation of metabolites of stanozolol in human urine by liquid chromatography tandem mass spectrometry. Steroids. October 2009. doi:10.1016/j.steroids.2009.05.004 · PMID 19464304
26. Other Baselt R. Disposition of Toxic Drugs and Chemicals in Man. 2008
27. Journal / agency Helfman T, Falanga V. Stanozolol as a novel therapeutic agent in dermatology. Journal of the American Academy of Dermatology. August 1995. doi:10.1016/0190-9622(95)90244-9 · PMID 7622653
28. Journal / agency Levin J, Trafford JA, Bishop PM. Stanozolol, a new anabolic steroid. The Journal of New Drugs. 1962. doi:10.1177/009127006200200106 · PMID 14464563
29. Journal / agency Promoting Safe and Effective Drugs for 100 Years
30. Journal / agency FDA aims to remove unapproved drugs from market: Risk-based enforcement program focuses on removing potentially harmful products. August 2008
31. Other The Drug Efficacy Study of the National Research Council's Division of Medical Sciences, 1966-1969
32. Journal / agency Food and Drug Administration Notice.DESI 7630. Certain Anabolic Steroids. Drugs for Human Use: Drug Efficacy Study Implementation. Federal Register. 24 June 1970
33. Other Food and Drug Administration Notice. Docket No 80N-0276; DESI 7630. Winstrol Tablets; Drugs for Human Use; Drug Efficacy Study Implementation, Revocation of Exemption; Followup Notice and Opportunity for Hearing on Proposal to Withdraw Approval of New Drug Federal Register, April 23, 1984. page 17094-99
34. Other Food and Drug Administration Notice. Docket No 80N-0276; Drugs for Human Use; Drug Efficacy Study Implementation; Conditions for Continued Marketing of Anabolic Steroids for Treatment Federal Register Vol 45 No. 213. October 31 1980. pages 72291-93
35. Other The Pink Sheet 30 April 1984 Sterling Winstrol (Stanozolol) NDA Withdrawal Process Beginning, FDA
36. Journal / agency Collins JC, Gwilt JR. The Life Cycle of Sterling Drug, Inc. Bull. Hist. Chem. 2000
37. Other Kodak to Sell Drug Unit for $1.68 Billion. June 24, 1994
38. Other Products
39. Other Press release: Ovation Pharmaceuticals Acquires Mebaral(R), Chemet(R), and Winstrol(R) From Sanofi-Synthelabo Inc. 7 August 2003
40. Other Press Release: GTCR Completes the Sale of Ovation Pharmaceuticals to Lundbeck. 19 March 2009
41. Other Novartis Pharmaceuticals Corp. et al.; Withdrawal of Approval of 27 New Drug Applications and 58 Abbreviated New Drug Applications. 21 July 2010
42. Journal / agency FDA Drugs@FDA: Stanozolol
43. Other The US Hereditary Angioedema Association Treatments
44. Other Craig TJ, Kalra N. Contemporary Issues in Prophylactic Therapy of Hereditary Angioedema. 30 July 2012
45. Other Zoetis. 24 June 2013 Zoetis Press Release: Zoetis Becomes Fully Independent With Acceptance of Pfizer Shares Tendered in Exchange Offer. link 2
46. Other Implantation or Injectable Dosage Form New Animal Drugs; Change of Sponsor. 20 May 2014
47. Other Oral Dosage Form New Animal Drugs; Change of Sponsor. 25 March 2014
48. Other Riviere JE, Papich MG. Veterinary Pharmacology and Therapeutics. 2013
49. Other Delves PJ. Merck Manual. March 2014
50. Other Morton IK, Hall JM. Concise Dictionary of Pharmacological Agents: Properties and Synonyms. 6 December 2012
51. Other Karch SB. Pathology, Toxicogenetics, and Criminalistics of Drug Abuse. 2007
52. Other Shänzer W. Testosterone: Action, Deficiency, Substitution. 2004
53. Journal / agency Ozcagli E, Kara M, Kotil T, Fragkiadaki P, Tzatzarakis MN, Tsitsimpikou C, Stivaktakis PD, Tsoukalas D, Spandidos DA, Tsatsakis AM, Alpertunga B. Stanozolol administration combined with exercise leads to decreased telomerase activity possibly associated with liver aging. International Journal of Molecular Medicine. July 2018. doi:10.3892/ijmm.2018.3644 · PMID 29717770 · PMC5979936
54. Other What is Stanozolol? Education, Science, Spirit of Sport / April 29, 2015. 29 April 2015

Text and values on this page are quoted from Wikipedia (CC BY-SA 4.0), PubChem (public domain). Each value links to the exact revision it came from.